Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	57M 66.07M 52.41M 49.33M 92.69M 6.24B 93.47M 621M 242M 3.06B 248M 243M 10.59B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	57M 66.07M 52.41M 49.33M 92.69M 6.24B 93.47M 621M 242M 3.06B 248M 243M 10.59B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	55.19%	Yield 2026 *	-	Yield 2027 *	-

06-09	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
06-09	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI
06-09	Pentixapharm Gains US FDA Clearance for Late-stage PentixaFor Study	MT
06-09	Pentixapharm to Raise EUR20 Million via Capital Increase	MT
06-09	Pentixapharm Holding AG Announces Positive Feedback From FDA For Initiation Of Phase III PANDA Study With [68Ga]Ga-PentixaFor	CI
05-11	Pentixapharm Holding AG Announces IND Submission To FDA For Phase 3 PANDA Study Of CXCR4-Targeted Cardiovascular Diagnostic	CI
05-07	Pentixapharm Holding Ag Reaffirms Earnings Outlook for the Full Year 2026	CI
05-06	Pentixapharm Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Pentixapharm Holding AG Appoints Erik Merten to the Executive Board	CI
03-26	Pentixapharm Holding AG Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-25	Pentixapharm Holding AG Auditor Raises 'Going Concern' Doubt	CI
02-25	Pentixapharm Holding AG Receives FDA " Study May Proceed" Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program	CI
02-05	Pentixapharm Holding Ag Announces Publication of New Phase 2 Clinical Data in the Journal of Nuclear Medicine	CI

06-09	[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market	EQ
06-09	Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program	EQ
05-11	Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic	EQ
05-10	Pentixapharm : Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic	PU
05-07	Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum	EQ

06-12	Pentixapharm : Annual General Meeting (Pentixapharm Hauptversammlung 2026 Prasentation)
06-09	[68Ga]Ga-PentixaFor in Primärem Aldosteronsimus: Mil-liardenpotenzial in einem unterversorgten Massenmarkt
06-09	Pentixapharm gibt FDA-Freigabe der Phase-3-Studie PANDA bekannt: Grünes Licht für ein kardiovaskuläres First-in-Class Diagnostikprogramm
06-09	Pentixapharm Holding AG: FDA erteilt „Study May Proceed“ für Phase-3-Studie; beabsichtigte Bezugsrechtskapitalerhöhung von bis zu 10 Mio. Aktien; BaFin-Bilanzkontrolle des Konzernabschlusses
05-11	Pentixapharm gibt IND-Einreichung bei der FDA für die Phase-3-Studie PANDA mit erstem CXCR4-gerichtetem kardiovaskulärem Diagnostikum bekannt

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	-.--%	-.--%	-	-	66.14M
ELI LILLY AND COMPANY	-0.58%	-1.87%	+40.93%	+146.73%	1,001B
JOHNSON & JOHNSON	-0.72%	-2.04%	+53.32%	+42.34%	566B
ABBVIE INC.	-0.27%	-1.25%	+19.76%	+61.17%	393B
ROCHE HOLDING AG	+3.82%	+2.29%	+24.04%	+16.53%	326B
NOVARTIS AG	+1.09%	+1.65%	+26.61%	+33.19%	276B
ASTRAZENECA PLC	+1.42%	+0.06%	+26.36%	+15.68%	277B
NOVO NORDISK A/S	+1.87%	+0.87%	-41.49%	-47.26%	193B
AMGEN INC.	-0.46%	+2.77%	+19.66%	+51.83%	188B
GILEAD SCIENCES, INC.	-0.55%	+4.50%	+17.55%	+63.36%	158B
Average	+0.05%	+0.35%	+20.75%	+42.62%	375.2B
Weighted average by Cap.	-0.20%	-0.41%	+29.57%	+66.45%

Pentixapharm Holding AG Stock OTC Markets

Stocks

PTPDF

DE000A40AEG0

Pharmaceuticals

Valuation: Pentixapharm Holding AG

Latest news : Pentixapharm Holding AG

Press Releases: Pentixapharm Holding AG

News in other languages: Pentixapharm Holding AG

Other Pharmaceuticals

Financials

Company Profile

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-